Keybanc analyst Sophie Karp initiates coverage on NEXTracker (NASDAQ:NXT) with a Sector Weight rating.
Fulcrum Therapeutics Q3 EPS $(0.51) Beats $(0.62) Estimate, Sales $1.18M Miss $2.54M Estimate
Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.62) by 17.74 percent. This is a 10.53 percent increase over losses of $(0.57) per share